Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Martineau who wrote (1897)	4/6/1998 9:43:00 PM
From: Perry	Read Replies (2) \| Respond to of 4676

Daniel thanks for your response. I agree that cancer promotion and progression involves numerous mutational events, however there is not doubt that certain key mutations in tumor suppressor genes (e.g. p53 mutations in lung cancer) and oncogenes (e.g. K-ras mutations in various organs) can be specifically targeted. These mutations are hypothesized to be the critical determinants for many cancers and if ISIS can block the over activity of oncogenes, which are responsible for unregulated tumor proliferation we may yet have a stock worth holding for years to come. In fact ISIS has performed numerous studies that have specifically targeted the mutational hot spots of ras gene/mRNA and have proved that antisense can not only bind specifically to this region but can also significantly reduce tumor cell growth. Only time will tell if antisense is a viable technology, but I'm putting my money where my mouth is, but I'm not holding my breath. Good luck, Perry